Symbols

ALKS

Alkermes·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 3

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

RSI Overbought

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ALKS

Alkermes Public Limited Company

A global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience

Industry

Pharmaceutical

Established Date

05/04/2011

Listing Date

07/16/1991

Exchange

NASDAQ Stock Exchange

Full-time Employees

2,050

Fiscal Year Ends

12-31

Website

www.alkermes.com

Security Type

Common stock

Office address

Connaught House 1 Burlington Road Dublin 4 Ireland D04 C5Y6

Business

Introduction

Alkermes Public Limited Company was established in Ireland as a private limited company on May 4, 2011 under the name Antler Science Two Limited (Registration No. 498284). The company is a fully integrated global biopharmaceutical company that leverages its scientific expertise and proprietary technology to develop innovative medicines that improve patient outcomes. The Company has a diversified product portfolio including more than 20 commercial drug products and a large number of clinical candidates for the treatment of central nervous system diseases such as addiction, schizophrenia and depression.

Company Financials

EPS

ALKS has released its 2025 Q4 earnings. EPS was reported at 0.29, versus the expected 0.41, missing expectations. The chart below visualizes how ALKS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ALKS has released its 2025 Q4 earnings report, with revenue of 384.55M, reflecting a YoY change of -10.57%, and net profit of 49.34M, showing a YoY change of -66.32%. The Sankey diagram below clearly presents ALKS's revenue sources and cost distribution.